endocrine therapy
1 product
43 abstracts
Abstract
Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.Org: SOLTI Cancer Research Group, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Vall d’Hebron Institute of Oncology,
Abstract
A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.Org: City of Hope Comprehensive Cancer Center, Translational Genomics Research Institute (TGen North), Cedars-Sinai Medical Center,
Abstract
Implementing geriatric assessment for dose optimization of CDK 4/6 inhibitors in older breast cancer patients (IMPORTANT trial): A pragmatic randomized-controlled trial.Org: Örebro University Hospital, Santo Stefano Hospital, General Hospital of Patras St. Andrews, Akershus University Hospital (Ahus), Papageorgiou General Hospital,
Abstract
International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor.Org: Dana-Farber Cancer Institute, Institut Jules Bordet, Université Libre de Bruxelles, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Centro de Pesquisa Clínica Hospital São Lucas da PUCRS,
Abstract
Prevalence of recreational and medical cannabis products in Veterans and their interactions with cancer directed pharmacological treatment.Org: University of Tennessee Health Science Center, University of Tennessee of Health Science Center, Kirkland Cancer Center, Baptist Memorial Hospital - Collierville, Lt. Col. Luke Weathers Jr. VA Medical Center,
Abstract
Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.Org: David Geffen School of Medicine at UCLA, University of California Irvine, Jonsson Comprehensive Cancer Center, Los Angeles, CA, Gilead Sciences, Inc.,
Abstract
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).Org: Dana-Farber Cancer Institute, Mayo Clinic, Medical University of Vienna, Washington University School of Medicine, The University of Texas MD Anderson Cancer Center,
Abstract
Real-world comparison of the efficacy of three CDK4/6 inhibitors (CDK4/6i) in the first-line treatment of endocrine-sensitive advanced breast cancer (aBC): Single institution experience.Org: School of Medicine, University of Zagreb, Department of Pathology, University Hospital Center Zagreb, Department of Pathology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Center,
Abstract
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.Org: Hospital del Mar, Barcelona, Spain, CIBERONC-ISCIII, Biovica International AB, Hospital Clínico Universitario de Valencia, INCLIVA-Biomedical Research Institute,
Abstract
Neoadjuvant targeted therapy in early resectable HER2-mutant lobular breast cancer.Org: Vanderbilt-Ingram Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, UT Southwestern Simmons Comprehensive Cancer Center,
Abstract
Optimization of surgical management of the axilla since MonarchE trial.Org: Georges François Leclerc Comprehensive Cancer Care Centre, Centre Georges François Leclerc, Centre Georges Francois Leclerc,
Abstract
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Harbin Medical University Cancer Hospital,
Abstract
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Sarah Cannon Research Institute/Tennessee Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Pfizer, Inc.,
Abstract
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.Org: Royal Cancer Hospital, Heidelberg University, Department of Oncology, National Taiwan University Hospital, Asan Medical Center, Service de Oncología Médica,
Abstract
Association of Medicaid expansion with treatment receipt, delays in treatment initiation, and survival among young adult women with breast cancer.Org: American Cancer Society, Mayo Clinic, Emory University School of Medicine,
Abstract
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.Org: Université Libre de Bruxelles (ULB), Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium, Breast International Group, Brussels, Belgium, Dana-Farber Cancer Institute, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race.Org: University of Hawaii John A. Burns School of Medicine, University of Hawaii Cancer Center,
Abstract
Impact of endocrine therapy adherence on racial disparities in breast cancer survival.Org: H. Lee Moffitt Cancer Center and Research Institute, Moffitt Cancer Center, University of Texas MD Anderson Cancer Center,
Abstract
Validation of a novel and rapid reagent free assay to predict outcomes for adjuvant therapy decision making in hormone receptor-positive breast cancer.Org: Imperial College, Imperial College London, Nottingham University Hospitals Trust, Rush University Medical College, Barts Cancer Institute,
Abstract
Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas.Org: University of Texas MD Anderson Cancer Center, BostonGene Corporation, BostonGene, Corp.,
Abstract
The impact of the 4R Oncology model of team-based care delivery on timing and sequence of guideline recommended interdependent care in breast and lung cancers.Org: Center for Business Models on Healthcare, Glencoe, IL, Genentech Inc, South San Francisco, CA, Albert Einstein College of Medicine, Bronx, NY, Northwestern University Feinberg School of Medicine, Chicago, IL,
Abstract
Trends and outcomes of systemic therapy in hormone receptor-positive early-stage male breast cancer: A propensity score analysis.Org: Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, China, Nosocomial Infection Control Branch, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, Fujian Province, 350001, China, Fujian Center for Disease Control and Prevention, Fuzhou, Fujian, China, Johns Hopkins University, Baltimore, MD,
Abstract
Primary efficacy analyses of NeoRHEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer.Org: Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Université Libre de Bruxelles, Academic Trials Promoting Team (ATPT), Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B.),
Abstract
SMALL: Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer—A UK phase III randomised multi-centre trial.Org: Queen's University Belfast, University of Cambridge, University of Oxford, Western General Hospital, University of Birmingham,
Abstract
African American women who carry the BRCA1/2 mutation: Clinical characteristics and prevention strategies.Org: Corewell Health System - Beaumont University Hospital, William Beaumont University Hospital, Beaumont Health, Oakland University William Beaumont Medical School,
Abstract
Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: A systematic review and network meta-analysis.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Incidental discovery of second primary malignancies in patients diagnosed with breast cancer: An institutional case series.Org: Temple University Hospital, Philadelphia, PA, University of Washington/Fred Hutchinson Cancer Research Center, University of Washington and Fred Hutchinson Cancer Research Centre, University of Washington, Cancer Vaccine Institute, Fred Hutchinson Cancer Research Center,
Abstract
Clinicopathological characteristics, treatment patterns, and prognosis of male breast cancer: China versus the United States.Org: Breast Disease Center, West China Hospital, Sichuan University, The First Affiliated Hospital of Sun Yat-sen University, The Fifth Medical Center of Chinese PLA General Hospital,
Abstract
Evaluating the impact of exercise in women living with indolent metastatic breast cancer: The EMBody trial.Org: IU School of Medicine, IUPUI School of Health and Human Sciences, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, METAvivor, Project Life,
Abstract
Side effects and impacts of extended adjuvant endocrine therapy: A qualitative study among women with HR+/HER2- breast cancer.Org: RTI Health Solutions, Sanofi, University of North Carolina School of Medicine,
Abstract
Patient-level interventions to increase guideline concordant treatment among Black breast cancer patients: Can they close the racial gap in survival after diagnosis?Org: University of North Carolina at Chapel Hill, University of North Carolina School of Medicine, The University of North Carolina at Chapel Hill,
Abstract
Breast cancer staging for patients with “low risk” disease: Are they all the same?Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Duke University Medical Center, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute,
Abstract
Objective assessment of fatigue, sleep and insomnia in breast cancer survivors on estrogen deprivation therapy.Org: University of South Carolina School of Medicine, Greenville, Greenville, SC, University of Kansas School of Nursing, Kansas City, KS, University of South Carolina School of Medicine Greenville, Greenville, SC, Prisma Health, Greenville, SC, Greenville Health System, Greenville, SC,
Abstract
Clinicopathological characteristics, evolution, treatment patterns and outcomes of hormone-receptor-positive/HER2-low-positive metastatic breast cancer: A retrospective analysis.Org: Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center,
Abstract
Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa Hospital Research Institute,
Abstract
Racial/ethnic differences in 21-gene recurrence score and survival among estrogen receptor-positive breast cancer patients.Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, The State University of New York, Buffalo, NY, Roswell Park Comprehensive Cancer Center, University of Florida COM,
Abstract
Does community size impact survival with breast cancer? Data from a large population-based cohort in British Columbia.Org: BC Cancer-Vancouver Centre, British Columbia Breast Cancer Outcomes Unit, Breast Cancer Outcomes Unit, BC Cancer Agency Vancouver Island Centre, University of British Columbia,
Abstract
Accelerated partial breast irradiation (APBI) for ductal carcinoma in situ.Org: Memorial Sloan Kettering Cancer Center, Montvale, New York Oncology Hematology PC, Tarrytown, NY, MSKCC,
Abstract
Prognostic significance of estrogen receptor status in de novo metastatic breast cancer.Org: Cangzhou Clinical College of Integrated Traditional Chinese and Western Medicine of Hebei Medical University,
Abstract
Cost-effectiveness of novel systemic therapies for advanced breast cancer: Global representativeness and influence of funding.Org: Instituto do Câncer do Estado de São Paulo (ICESP), University of São Paulo/ICESP, São Paulo, SP, Brazil, Sao Paulo State Cancer Institute (ICESP), São Paulo, Brazil,
Abstract
Long-term longitudinal patterns of patient-reported quality of life (QOL) after breast cancer (BC) to inform the implementation of personalized pathways of care.Org: Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Département d'Organisation du Parcours Patient, Villejuif, France, Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy, Villejuif, France,
Abstract
From the lab to the clinic: Lessons learned from a translational working group.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Division of Surgical Oncology, Department of Surgery, The Ohio State University, Durham, NC, COMET Study Patient Leadership Team, San Francisco, CA,
Abstract
The impact of 4R Care Delivery Model on timing and sequence of bone density screening among breast cancer patients.Org: Kaiser San Francisco, Northwestern University Feinberg School of Medicine, Center for Business Models on Healthcare, Division of Research Services, Kaiser Permanente Northern California,
Product
endocrine therapy alone